_:n708cc81e1c7e412a8f30ccaf2c5e7cf4xb0
<http://schema.org/description>
"The use of isotretinoin therapy in dermatology has become complicated by regulatory and medicolegal issues. Still, isotretinoin for severe acne has been a mainstay of dermatologic therapy since its Food and Drug Adminstration approval in 1982. While dermatologists have become adept at addressing the drug's well-known teratogenic adverse effects and potential associations with depression and suicidal ideation, a knowledge gap may exist for many dermatologists to address clinical care questions related to isotretinoin therapy and IBD. The article by Popescu and Popescu 1 in this issue of Archives helps to narrow this gap and potential knowledge gaps related to general epidemiologic principles about causation."
<https://jamanetwork.com/journals/jamadermatology/article-abstract/423903>